Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Woman Suffered From Leukocytopenia and Widespread Migration After Polyacrylamide Hydrogel (PAAG) Injection in Epicranial Aponeurosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Duo Zhang, First Hospital of Jilin University
ClinicalTrials.gov Identifier:
NCT01519362
First received: January 24, 2012
Last updated: January 25, 2012
Last verified: January 2012
  Purpose

Polyacrylamide hydrogel (PAAG) has been used as an injectable filler for soft tissue augmentation in different parts of the body , such as face, breast , or even penis for more than a decade . However, there are never reports about the application of a large amount of PAAG in epicranial aponeurosis to change the contour of the upper cranium accompanied with leukocytopenia. This fancy application turned out to be a disaster for the women who suffered from leukocytopenia , widespread migration of PAAG, recurrent swelling of the affected tissues and temporal pain changing with the temperature and the facial expression .


Condition
Complication

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective

Further study details as provided by First Hospital of Jilin University:

Enrollment: 1
Study Start Date: October 2011
  Eligibility

Ages Eligible for Study:   50 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

A 50-year-old lady had PAAG injected into her bilateral temporal epicranial aponeurosis for augmentation

Criteria

Inclusion Criteria:

  • PAAG injected into bilateral temporal epicranial aponeurosis

Exclusion Criteria:

  • PAAG injected into other parts of the body
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Duo Zhang, professor, First Hospital of Jilin University
ClinicalTrials.gov Identifier: NCT01519362     History of Changes
Other Study ID Numbers: zhangduo
Study First Received: January 24, 2012
Last Updated: January 25, 2012
Health Authority: China: Ethics Committee

Keywords provided by First Hospital of Jilin University:
Polyacrylamide hydrogel
leukocytopenia
migration
complication
epicranial aponeurosis
PAAG injection

ClinicalTrials.gov processed this record on November 27, 2014